Found: 5
Select item for more details and to access through your institution.
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
- Published in:
- Calcified Tissue International, 2023, v. 112, n. 6, p. 631, doi. 10.1007/s00223-023-01078-z
- By:
- Publication type:
- Article
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
- Published in:
- Archives of Osteoporosis, 2023, v. 18, n. 1, p. 1, doi. 10.1007/s11657-023-01211-3
- By:
- Publication type:
- Article
OP52 Treating Osteoporosis In Postmenopausal Women With Denosumab (Prolia®): A Systematic Review And Network Meta-Analysis.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, p. S14, doi. 10.1017/S0266462323000831
- By:
- Publication type:
- Article
OP70 Treating Patients With Hormone-Sensitive Cancer On Endocrine Therapy With Denosumab (Prolia®): A Systematic Review And Network Meta-Analysis.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, p. S19, doi. 10.1017/S0266462323000946
- By:
- Publication type:
- Article
OP129 A Cost-Utility Analysis Of Denosumab (Prolia®) For Treating Osteoporosis In Postmenopausal Women: A Swiss Healthcare Payer Perspective.
- Published in:
- International Journal of Technology Assessment in Health Care, 2023, v. 39, p. S37, doi. 10.1017/S0266462323001344
- By:
- Publication type:
- Article